Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial

Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms

“…Data have shown that lower doses of radiation may be less effective in preventing CNS failures [42,50]. Le Pé-choux et al [52] published the results of a large international study evaluating radiation dose for PCI in SCLC. Between September 1999 and December 2005, 720 patients with LS-SCLC in complete remission after chemotherapy and TRT from 157 centers in 22 countries were randomly assigned to standard-dose PCI to 25 Gy in 10 daily fractions or higher-dose PCI to 36 Gy delivered in 10 fractions of 2 Gy once daily or 16 fractions of 1.5 Gy twice daily.…”

Clinical Results of Stereotactic Body Radiotherapy for Stage I Small Cell Lung Cancer: A Single Institutional Experience

“…Recently, the role of PCI has been established in the treatment of SCLC, especially in LD-SCLC [20,21]. In our series, no patients suffered from brain metastasis, despite not undergoing PCI.…”

Radiation Therapy in Management of Small-Cell Lung Cancer

“…The study randomized 720 LS-SCLC patients from 157 centers to one of two PCI arms: Arm-1 included patients receiving standard-dose PCI to 25 Gy in 2.5 Gy per fraction, and Arm 2 included patients receiving higher dose PCI to 36 Gy delivered in 2 Gy once daily or 1.5 Gy twice daily. No significant difference of BM incidence was reported between two study arms, but there was a significantly higher rate of cancer-related mortality in the higher dose arm as a result of unexplained finding of more deaths from extracranial disease progression (Le Pechoux et al, 2009). Based on the results of this study, 25 Gy delivered at 2.5 Gy per fraction per day remains the standard of care for PCI in LS-SCLC patients.…”